Regulatory Focus™ > News Articles > 3 > Recon: Walmart in Talks to Buy Humana

Recon: Walmart in Talks to Buy Humana

Posted 30 March 2018 | By Ana Mulero 

Recon: Walmart in Talks to Buy Humana

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.

In Focus: US In Focus: International Pharmaceuticals & Biotechnology
  • The Call For Drug-Price Transparency Is Growing Louder -- But Will It Matter? (Forbes)
  • Will flush-with-cash Big Pharma beat Takeda to a Shire deal? (Fierce)
  • Thermo Fisher, Biocept team up to pitch liquid biopsy service to pharma (Fierce) (Press)
  • Cash reserves running low at KemPharm (Fierce) (Press)
  • LISTEN: A billionaire intervenes, inscrutable drug prices, and no grade inflation for biotechs (STAT)
  • Gottlieb slams PBMs (BioCentury)
  • FDA charts path forward for biosimilars — but drug makers aren’t all on board (STAT-$)
  • Sage Therapeutics CEO: Have to weigh investor returns but will price postpartum drug ‘fairly’ (CNBC)
  • Two Harvard Biotech Entrepreneurs Are Creating The "Trojan Horse" Of Cancer Treatment (Forbes)
  • Lilly seeks to quickly advance—and if needed kill—novel drugs to avoid ‘pile-on effect’ in hot targets (Fierce)
  • Students push UCLA to improve access to a cancer drug developed by its scientists (STAT-$) (The Wire)
  • Novartis and GSK CEOs set out diverging strategies (Financial Times-$)
Pharmaceutical and Biotechnology: Study Results, Filings and Designations
  • Gene therapy could promote healing in brain, spinal cord injuries (Fierce)
  • Sunovion Submits New Drug Application to the FDA for Apomorphine Sublingual Film (APL-130277) for the Treatment of OFF Episodes Associated with Parkinson’s Disease (Press)
  • NIH study may help explain why iron can worsen malaria infection (NIH)
  • Study in pregnant women hints at pertussis protection from flu vaccination (CIDRAP)
  • Targeting stress proteins on cells to help treat cancer (BioCentury)
  • Mallinckrodt Inc. et al.; Withdrawal of Approval of Five New Drug Applications (FDA)
Medical Devices
  • Study shows promise for detecting mental health problems using smartphone app (Fierce)
  • US FDA Panel To Tackle Hospital Glucose Meter Accuracy Issue (Medtech Insight)
  • These medical devices offer hope for treating chronic pain without opioids (CNBC)
  • T2 Biosystems touts results from 4 studies of its T2Dx diagnostics system (MassDevice)
  • Quest Beats Out-Of-Pocket Overcharge Suit, For Now (Law360-$)
  • A medical-grade smartwatch is helping people live with epilepsy (Wired)
  • Is 3D printing going to replace injection molding? (Medical Design & Outsourcing)
  • Foundation Medicine launches genomic profiling test for solid tumors (Drug Delivery Business News) (Press)
  • FDA committee backs Senseonics’ implantable continuous glucose monitor (Drug Delivery Business News) (Press)
  • NuVasive touts Porous PEEK interbody implant study (MassDevice)
US: Assorted & Government
  • Trump wants to reduce opioid prescriptions by one-third. We can start now (STAT)
  • Why Would Walmart Want to Buy an Insurer? The Retail Squeeze (WSJ)
  • On Medicare? Check the mail for your new, secure ID card (CNBC)
  • FDA may consider over-the-counter regulation for e-cigarettes (CNBC)
  • Prevalence of Diagnosed Diabetes in Adults by Diabetes Type — US, 2016 (CDC)
  • Survey Snapshot: Payer-Provider Alignment Is Difficult Even for Integrated Organizations (NEJM)
Upcoming Meetings & Events Europe
  • EMA accepts BioMarin's pegvaliase MAA to treat phenylketonuria (Pharmabiz) (Press)
  • Biovica announces new positive results support early treatment evaluation of breast cancer using DiviTum (Pharmabiz)
  • Medicrea inks Belgian JV deal with Motion Medical (MassDevice)
  • TAP Blood Collection Device Receives CE Mark (Press)
  • MIVI Neuroscience Begins European Commercialization After Achieving CE Mark Approval Of The R4Q Revascularization Catheter For Ischemic Stroke (Press)
  • New government initiative to reduce rough sleeping (MHRA)
Asia
  • TPG Said to Pursue Stake in $500 Million Thai Fertility Hospital (Bloomberg) (Business Standard)
  • Dr. Reddy's Labs appoints Erez Israeli as new chief operating officer (Pharmabiz)
  • New chairman for Workplace Safety and Health Council (The Straits Times)
  • Taiwan's National Health Insurance advances WHO goal of universal coverage (The Korea Times)
India
  • Is hospital care getting prioritised over primary healthcare in India? (Asian Age)
  • CDSCO discontinues joint inspection of manufacturing units offering loan licenses in Maharashtra (Pharmabiz)
  • BeatO is India’s first full stack digital solution for managing diabetes (Pharmabiz)
Australia
  • Royal flying doctors funded to provide mental health outreach for first time (The Guardian)
  • A data bungle put at risk the private health details of millions of Australians (Business Insider)
  • Transvaginal mesh use should be suspended, health groups say (The Guardian)
Canada
  • 1 in 66 Canadian children diagnosed with autism, report reveals (CBC News)
  • Veritas Pharma Closes Private Placement (Press)
  • Salmonella outbreak from raw chicken products leads to 30 cases in Canada (CBC News)
  • Canada's largest health research platform teams up with University of Toronto to accelerate cancer and chronic disease research (Press)
General Health & Other Interesting Articles
  • Starbucks coffee in California must have cancer warning, judge says (Reuters)
  • Hawaii lawmakers approve bill to legalize physician-assisted suicide (The Hill) (Reuters)
  • Customer Service In Assisted Living, Homecare And Healthcare: The 'Required Hospitality' Difference (Forbes)
Regulatory Reconnaissance is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory news stories from around the globe. Each weekday morning, we aim to bring you the latest highlights of new approvals, meetings, legal and political developments, regulations and guidance, and the latest trends with the potential to impact regulatory affairs professionals and the industry in which they work.

Need to contact the editor of Regulatory Reconnaissance? Email us at news@raps.org.

A story's inclusion in Regulatory Reconnaissance does not imply endorsement by Regulatory Focus or RAPS.
 

Categories: Recon

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe